Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 15/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23177820 | 0.86 | L3MBTL1 (0.79) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL751185 | 0.83 | L3MBTL1 (0.65) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL8369000 | 0.83 | L3MBTL1 (0.60) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL3604433 | 0.83 | L3MBTL1 (0.60) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL31519821 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL23177713 | 0.79 | L3MBTL1 (0.56) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL4944588 | 0.79 | HDAC3 (0.60) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL3614658 | 0.78 | L3MBTL1 (0.55) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL19700183 | 0.76 | L3MBTL1 (0.56) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL3101917 | 0.76 | L3MBTL1 (0.68) | L3MBTL1KCNQ2MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038917-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038920-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-110511220-B | P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine | 上海挚盟医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2021-06-03 | — | — | US | disclosed |
| EP-3798220-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2021-03-31 | — | — | EP | disclosed |
| EP-3798220-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2021-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | L3MBTL1 4803/4885KCNQ2 16/4885MEN1 1182/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | L3MBTL1 4792/4885KCNQ2 16/4885MEN1 1160/4885 |
| US-20210163429-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | L3MBTL1 4792/4885KCNQ2 16/4885MEN1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.